Bioequivalence of Phenazopyridine HCl in Healthy Volunteers
2 Treatment, 2 Period, Randomized, Single Blinded, Crossover Bioequivalence of Phenazopyridine HCl in 24 Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Karachi, Pakistan
- Health Care Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subjects aged 18 to 55 (Male & Female)
- Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests
- Informed consent signed by the subject
- The subject is co-operative and available for the entire study
- Not pregnant or nursing
- Normal renal and hepatic function
Exclusion Criteria:
- Evidence in the subject medical history or in the medical examination of any clinically significant hepatic, renal, gastrointestinal, cardiovascular, pulmonary, hematological or other significant acute or chronic abnormalities which might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the active agent under investigation
- Hypersensitivity to subject drug, atopic eczema or allergic bronchial asthma
- Evidence of hypertension (blood pressure after 3 minutes sitting>160/95 mm Hg)
- Evidence of chronic or acute infectious diseases;
- History or evidence of malignant tumors;
- Evidence of hyperuricaemia, elevated serum uric acid (>8.0 mg/dl)
- Hepatic or renal impairment; elevated serum creatinine (>1.4 mg/dl)
- Planned vaccination during the time course of the study
- Adherence to a diet (i.e, vegetarian) or life style (incl. extreme sports) that might interfere with the investigation
- Laboratory test results outside the tolerance values as laid down by the study centre, which may be an evidence of disease. Positive result of HIV1/2, HCV antibody or HBs antigen testing
- Regular use of any medication within four weeks prior to commencement of the study (self-medication or prescription)
- Single use of any medication (including OTC) that are not expressively permitted within two weeks prior to start of the study
- Abuse of alcohol, caffeine or tobacco (equivalent to more than 10 cigarettes a day)
- Drug addiction
- Participation in a clinical investigation or blood donation of more than 250 ml within the past eight weeks or blood donation of less than 250 ml within the past 4 week
Subjects who are known or suspected
- not to comply with the study directives
- not to be reliable or trustworthy
- not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent),in particular regarding the risks and discomfort to which they would agree to be exposed.
- to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: A
|
100mg tablet in fasting state
Other Names:
|
|
Experimental: B
|
100mg tablet in fasting state
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary outcome of the study will be to determine the bioequivalence of both the formulations of phenazopyridine
Time Frame: regular intervals after drug dosing
|
regular intervals after drug dosing
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Waqar H. Kazmi, M.D, M.S.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- URG/STEROP/001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.